Last reviewed · How we verify
Guanfacine/Tenex
Guanfacine/Tenex is a Alpha-2A adrenergic receptor agonist Small molecule drug developed by Research Foundation for Mental Hygiene, Inc.. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, Hypertension.
Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity.
Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, Hypertension.
At a glance
| Generic name | Guanfacine/Tenex |
|---|---|
| Sponsor | Research Foundation for Mental Hygiene, Inc. |
| Drug class | Alpha-2A adrenergic receptor agonist |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
By selectively binding to alpha-2A adrenergic receptors in the prefrontal cortex and other brain regions, guanfacine decreases norepinephrine signaling, which improves attention, impulse control, and reduces hyperactivity. This mechanism makes it particularly useful for conditions characterized by prefrontal cortex dysfunction, such as ADHD and hypertension.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
- Hypertension
Common side effects
- Somnolence
- Fatigue
- Headache
- Dizziness
- Dry mouth
- Hypotension
- Bradycardia
Key clinical trials
- ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression (PHASE2)
- Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders (PHASE2)
- Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study (PHASE2)
- Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) (PHASE2)
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) (NA)
- Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance (PHASE4)
- AWARE: Management of ADHD in Autism Spectrum Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guanfacine/Tenex CI brief — competitive landscape report
- Guanfacine/Tenex updates RSS · CI watch RSS
- Research Foundation for Mental Hygiene, Inc. portfolio CI
Frequently asked questions about Guanfacine/Tenex
What is Guanfacine/Tenex?
How does Guanfacine/Tenex work?
What is Guanfacine/Tenex used for?
Who makes Guanfacine/Tenex?
What drug class is Guanfacine/Tenex in?
What development phase is Guanfacine/Tenex in?
What are the side effects of Guanfacine/Tenex?
What does Guanfacine/Tenex target?
Related
- Drug class: All Alpha-2A adrenergic receptor agonist drugs
- Target: All drugs targeting Alpha-2A adrenergic receptor
- Manufacturer: Research Foundation for Mental Hygiene, Inc. — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing